‘Race for the Cure’ Adds Nine New Sites

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 3
Volume 7
Issue 3

DALLAS--The Susan G. Komen Breast Cancer Foundation, producer of the country’s largest series 5K runs known as Race for the Cure, today announced nine new race sites for the 1998 series, bringing the total number of run/fitness walks to 86. Sites added include Austin, Texas; Evansville, Indiana; Grand Rapids, Michigan; Greeley, Colorado; Madison, Wisconsin; Richmond, Virginia; San Antonio, Texas; Thibodaux, Louisiana; and Tupelo, Mississippi.

DALLAS--The Susan G. Komen Breast Cancer Foundation, producer of the country’s largest series 5K runs known as Race for the Cure, today announced nine new race sites for the 1998 series, bringing the total number of run/fitness walks to 86. Sites added include Austin, Texas; Evansville, Indiana; Grand Rapids, Michigan; Greeley, Colorado; Madison, Wisconsin; Richmond, Virginia; San Antonio, Texas; Thibodaux, Louisiana; and Tupelo, Mississippi.

More than 500,000 runners and walkers are expected to participate in 1998’s Race for the Cure. In 1997, more than 445,000 runners and walked participated in the national series, representing a 37% increase over 1996.

Proceeds from the race go to both national research efforts and local breast cancer initiatives. "What truly sets the Komen Foundation apart is its depth on a community level," said Nancy Brinker, president and founder.

Recent Videos
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
Related Content